Fiona T. Bane

St Stephens Green
Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Correction: ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.

Correction: ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.

Journal: BMC medicine

Published: December 13, 2025

Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.

Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.

Journal: Journal of the National Cancer Institute

Published: February 17, 2025

ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2.

ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2.

Journal: Endocrine-related cancer

Published: November 26, 2024

Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers.

Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers.

Journal: Cancer communications (London, England)

Published: September 10, 2024

RET overexpression leads to increased brain metastatic competency in luminal breast cancer.

RET overexpression leads to increased brain metastatic competency in luminal breast cancer.

Journal: Journal of the National Cancer Institute

Published: June 15, 2023

Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer.

Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer.

Journal: Cancer communications (London, England)

Published: May 03, 2022

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.

Journal: Nature communications

Published: March 08, 2021

ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.

ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.

Journal: BMC medicine

Published: June 16, 2020

Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.

Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.

Journal: Oncogene

Published: May 13, 2020

Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.

Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.

Journal: Molecular cancer therapeutics

Published: July 17, 2018

Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.

Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.

Journal: Oncogene

Published: March 23, 2017

S100β as a serum marker in endocrine resistant breast cancer.

S100β as a serum marker in endocrine resistant breast cancer.

Journal: BMC medicine

Published: November 14, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026